
Rafael Hernani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7680876/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<scp>SARSâ€CoV</scp> â€2â€reactive antibody detection after <scp>SARSâ€CoV</scp> â€2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. American Journal of Hematology, 2022, 97, 30-42.	2.0	52
2	Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplantation, 2022, 57, 1389-1398.	1.3	10
3	Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection, 2021, 49, 215-231.	2.3	63
4	Ex vivo Tâ€cell depletion vs postâ€transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graftâ€vsâ€host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. European Journal of Haematology, 2021, 106, 114-125.	1.1	2
5	Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers. Transplantation and Cellular Therapy, 2021, 27, 493.e1-493.e8.	0.6	5
6	An investigation of the potential association between gastrointestinal viral and bacterial infection and development of intestinal acute graft versus host disease following allogeneic hematopoietic stem cell transplantation. Journal of Medical Virology, 2021, 93, 4773-4779.	2.5	1
7	Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. Bone Marrow Transplantation, 2021, 56, 1919-1928.	1.3	13
8	Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graftâ€versusâ€host disease prophylaxis. EJHaem, 2021, 2, 236-248.	0.4	4
9	Realâ€world evidence of tisagenlecleucel for the treatment of relapsed or refractory large Bâ€cell lymphoma. Cancer Medicine, 2021, 10, 3214-3223.	1.3	73
10	Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplantation, 2021, 56, 2432-2444.	1.3	33
11	CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review. Current Research in Translational Medicine, 2021, 69, 103304.	1.2	12
12	The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey. Bone Marrow Transplantation, 2020, 55, 431-440.	1.3	13
13	Clinical significance of Pneumocystis jirovecii DNA detection by real-time PCR in hematological patient respiratory specimens. Journal of Infection, 2020, 80, 578-606.	1.7	2
14	Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease, 2020, 23, e13507.	0.7	7
15	Cytomegalovirus DNA load monitoring in stool specimens for anticipating the occurrence of intestinal acute graftâ€versusâ€host disease following allogeneic hematopoietic stem cell transplantation: ls it of any value?. Transplant Infectious Disease, 2020, 22, e13440.	0.7	4
16	Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. Bone Marrow Transplantation, 2020, 55, 2147-2159.	1.3	24
17	Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease, 2020, 22, e13301.	0.7	7
18	Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies. Biology of Blood and Marrow Transplantation, 2020, 26, 972-977.	2.0	11

#	Article	IF	CITATIONS
19	Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups. Frontiers in Immunology, 0, 13, .	2.2	13